Welcome to our dedicated page for Compass Therapeutics SEC filings (Ticker: CMPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Compass Therapeutics, Inc. filings document a clinical-stage oncology biopharmaceutical company developing proprietary antibody-based therapeutics. Its SEC reports include Form 8-K disclosures for operating and financial results, Regulation FD updates, clinical data presentations and other material events related to tovecimig and the broader antibody pipeline.
The company’s definitive proxy materials cover annual meeting matters, director elections and stockholder voting procedures. Filing disclosures also address governance, equity compensation, capital-structure matters, cash resources, clinical and regulatory risk areas, and the public-company controls associated with a Nasdaq-listed development-stage biotechnology issuer.
Compass Therapeutics (CMPX) reported Q3 2025 results, highlighting a stronger balance sheet and continued R&D investment. Cash, cash equivalents and marketable securities were $220 million as of September 30, 2025, and management said this resources level is expected to fund operations into 2028.
Q3 operating expenses were $15.8 million, driven by research and development of $12.8 million (up 49% year over year) and general and administrative of $3.0 million (down 18%). Net loss for Q3 was $14.3 million, or $0.08 per share, and $50.8 million for the nine months.
The company completed an underwritten offering on August 12, 2025, issuing common stock and pre-funded warrants, for net proceeds of $129.3 million. As of October 30, 2025, shares outstanding were 177,862,102.
Pipeline updates included: analyses of overall survival and progression-free survival from the Phase 2/3 BTC study of tovecimig expected in late Q1 2026, and full topline Phase 1 data for CTX-8371 planned for the first half of 2026, with cohort expansions in NSCLC and TNBC planned this quarter.
Compass Therapeutics, Inc. filed a current report to share that it has released its financial results for the quarter and nine months ended September 30, 2025. The company reported these results via a press release dated November 5, 2025, which is attached to the report as an exhibit and incorporated by reference. The filing is focused on making this earnings information available to the market and does not itself detail the specific revenue, profit, or cash figures.
Compass Therapeutics, Inc. received an amendment to a Schedule 13G reporting that Suvretta Capital Management, LLC, Averill Master Fund, Ltd. and Aaron Cowen together filed ownership information for the issuer's common stock (CUSIP 20454B104). Suvretta reports beneficial ownership of 14,101,159 shares (8.2% of the class) with shared voting and dispositive power. Averill Master Fund reports 12,229,050 shares (7.1%) with shared voting and dispositive power. Aaron Cowen is reported with the same 14,101,159 shares (8.2%). The filing states these securities are directly owned by advisory clients of Suvretta, and the reporting persons disclaim beneficial ownership except to their pecuniary interest.
Amendment No. 1 to the Schedule 13D reports that a group of related reporting persons collectively beneficially own 7,788,150 shares of Compass Therapeutics common stock, representing 4.5% of the outstanding shares based on 171,572,498 shares outstanding as of the issuer's prospectus. The amendment states the ownership percentage declined due to a decrease in the issuer's outstanding shares, and as a result the reporting entities "ceased to exceed 5%" and are no longer subject to Section 13 reporting. The filing also confirms no transactions in the common stock by the reporting entities in the past 60 days and identifies the reporting persons and their shared voting and dispositive power over the disclosed shares.
OrbiMed Advisors LLC and OrbiMed Capital GP V LLC filed Amendment No. 6 to their Schedule 13D for Compass Therapeutics, Inc. to report that their beneficial ownership decreased to 15,219,994 shares, representing approximately 8.9% of the outstanding common stock. The decrease in percentage ownership is attributed to an increase in the number of shares outstanding as disclosed in the issuer's prospectus. OrbiMed GP is the general partner of the limited partner that holds the shares and OrbiMed Advisors is the managing member of OrbiMed GP, giving the reporting persons shared power to vote and dispose of the shares. Carl L. Gordon, a member of OrbiMed Advisors, serves on the issuer's board.
Compass Therapeutics (CMPX) Schedule 13G/A: Tang Capital affiliates and Kevin Tang report shared beneficial ownership of 13,496,208 shares of Compass Therapeutics common stock, representing 9.8% of the outstanding class based on 138,282,498 shares outstanding as of April 28, 2025. The filing states no sole voting or dispositive power; all 13,496,208 shares are held with shared voting and shared dispositive power among Tang Capital Management, LLC; Tang Capital Partners, LP; Tang Capital Partners International, LP; Tang Capital Partners III, Inc.; Tang Capital Partners IV, Inc.; and Kevin Tang. The filing certifies the holdings were not acquired to change or influence control of the issuer.
Amendment to Schedule 13G correcting an earlier administrative error. RTW Investments, LP and Roderick Wong state that, as of June 30, 2025, they did not beneficially own any ordinary shares of Compass Therapeutics, Inc.; the filing reports 0 shares and 0.0% ownership. RTW Investments is identified as an investment adviser to certain funds and Dr. Wong is identified as Managing Partner and Chief Investment Officer. The amendment clarifies that an earlier Schedule 13G related to this issuer was filed inadvertently and this filing corrects that error.
RTW Investments, LP and Roderick Wong filed an amended Schedule 13G reporting beneficial ownership of 9,474,397 Ordinary Shares of Compass Therapeutics, Inc. (CUSIP 20451W101). The filing states the reported position represents approximately 9.99% of the class when assuming exercise of warrants to purchase 1,252,468 shares and using 93,586,348 shares outstanding as of June 30, 2025. The Reporting Persons disclose no sole voting or dispositive power and share voting and dispositive power over the reported shares.
The filing notes the RTW Funds have rights to receive dividends or proceeds and identifies RTW Master Fund, Ltd. as holding rights to more than 5% of the reported shares. Issuer and filer addresses are provided in the filing.
Suvretta Capital Management, Averill Master Fund and Aaron Cowen filed a Schedule 13G reporting beneficial ownership of Compass Therapeutics common stock. Suvretta and Mr. Cowen each report shared voting and dispositive power over 7,149,493 shares, representing 5.2% of the class, while Averill Master Fund reports shared voting and dispositive power over 6,251,950 shares, representing 4.5% of the class. None of the reporting persons report sole voting or dispositive power.
Suvretta discloses that the reported securities are directly owned by its advisory clients and that none of those clients may be deemed to beneficially own more than 5% individually. The filers certify the holdings are held in the ordinary course of business and not for the purpose of changing or influencing control.
Compass Therapeutics, Inc. entered an underwriting agreement to sell 33,290,000 shares of common stock at $3.00 per share and pre-funded warrants to purchase up to 6,710,000 shares at $2.9999 per warrant with an exercise price of $0.0001 per share. The underwriters have a 30-day option to purchase up to an additional 6,000,000 shares.
The company estimates net proceeds of approximately $112.5 million (or approximately $129.5 million if the option is exercised in full) and expects closing on or about August 14, 2025. Compass intends to use proceeds to prepare for commercial readiness, fund research and clinical development, and for general corporate purposes, and states that, assuming $112.5 million net proceeds, its cash is expected to fund operations into 2028. The filing notes the company may use capital sooner than expected and will receive nominal proceeds, if any, from exercise of the pre-funded warrants.